THE OHIO STATE UNIVERSITY and the University of Michigan have signed an agreement with Ohio-based Venture Therapeutics Inc. to form a new company to develop and commercialize a pharmaceutical technology targeted for the treatment of precancerous oral lesions.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
